Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner

Novo Nordisk A/S NVO successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. 

Viatris Inc VTRS, via its subsidiary Mylan Pharmaceuticals, had instigated challenges aiming to pave the way for generic versions of these drugs but was thwarted by a decisive ruling from the U.S. Patent Office tribunal.

Mylan had argued that the patents were based on the anti-diabetes medication liraglutide and thus should be invalidated.

Also Read: Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?

Reinforcing Novo Nordisk's stance, Reuters noted, a spokesperson expressed the company's resolve to "vigorously defend" its intellectual property. 

Novo's Wegovy heralded as a forerunner in a novel class of efficacious weight-loss medications, has recorded flourishing sales trajectories. 

Analysts are optimistic, with projections indicating the obesity market's valuation potentially eclipsing $100 billion by the decade's closure.

Price Action: NVO shares are down 1.85% at $90.10 during the premarket session on the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.